Cell-Specific Computational Modeling of the PIM Pathway in Acute Myeloid Leukemia by Silverbush, D et al.
Cancer Research 
 
1 
 
Cell-Specific Computational Modeling of the PIM pathway in Acute 
Myeloid Leukemia 
 
Dana Silverbush1,2^, Shaun Grosskurth3^, Dennis Wang4,  Francoise Powell3, 
Berthold Gottgens5, Jonathan Dry3* and Jasmin Fisher2,6*  
 
1Department of Computer Science, Tel-Aviv University, Tel-Aviv, Israel;  
2Microsoft Research, Cambridge, UK;  
3AstraZeneca Oncology IMED, Waltham MA;  
4AstraZeneca Oncology IMED, Cambridge UK;  
5Department of Haematology, Cambridge Institute for Medical Research & Wellcome 
Trust and MRC Stem Cell Institute, University of Cambridge, UK;  
6Department of Biochemistry, University of Cambridge, UK 
 
^ These authors contributed equally to this work 
*To whom correspondence should be addressed:   
jf416@cam.ac.uk and jonathan.dry@astrazeneca.com 
Running title: Cell-Specific Computational Models of Acute Myeloid Leukemia 
Disclosure of Potential Conflicts of Interest: The authors have read and understood 
the AACR journal policy on reporting conflicts of interest and have no conflicts to 
disclose.  
Cancer Research 
 
2 
 
Abstract 
Personalized therapy is a major goal of modern oncology, as patient responses vary 
greatly even within a histologically defined cancer subtype. This is especially true in 
acute myeloid leukemia (AML), which exhibits striking heterogeneity in molecular 
segmentation. When calibrated to cell-specific data, executable network models can 
reveal subtle differences in signaling that help explain differences in drug response. 
Furthermore, they can suggest drug combinations to increase efficacy and combat 
acquired resistance. Here we experimentally tested dynamic proteomic changes and 
phenotypic responses in diverse AML cell lines treated with pan-PIM kinase inhibitor 
and fms related tyrosine kinase 3 (FLT3) inhibitor as single agents and in 
combination. We constructed cell-specific executable models of the signaling axis, 
connecting genetic aberrations in FLT3, tyrosine kinase 2 (TYK2), platelet derived 
growth factor receptor alpha (PDGFRA), and fibroblast growth factor receptor 1 
(FGFR1) to cell proliferation and apoptosis via the PIM and PI3K kinases. The 
models capture key differences in signaling that later enabled them to accurately 
predict the unique proteomic changes and phenotypic responses of each cell line. 
Furthermore, using cell-specific models, we tailored combination therapies to 
individual cell lines and successfully validated their efficacy experimentally. 
Specifically, we showed that cells mildly responsive to PIM inhibition exhibited 
increased sensitivity in combination with PIK3CA inhibition. We also used the model 
to infer the origin of PIM resistance engineered through prolonged drug treatment of 
MOLM16 cell lines and successfully validated experimentally our prediction that this 
resistance can be overcome with AKT1/2 inhibition. 
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Introduction 
The potential of personalized medicine is dependent on our ability to translate the 
molecular context of patients’ tumors into interpretable clinical outcomes. Successful 
steps have been taken to accurately predict tumor progression and response to 
treatment from molecular disease markers [1,2]. Using tumor cell line based 
compound screening, we can provide robust readouts of cellular responses to multiple 
compounds. This information can be used to systematically train computational 
models of the molecular signaling pathways contributing to drug sensitivity and 
resistance in various cancer settings, and to propose novel drug targets and 
combination approaches. Cell line screens have provided some success in explaining 
or predicting drug responses by driver gene mutations [2,3,4]; however in many cases 
the true mechanism of resistance remains elusive or more complex. Most predictive 
methods routinely used today employ correlative statistics or feature-based learning 
techniques such as machine learning, while network methods remain scarce despite 
their potential for extracting mechanistic insights and actionable biomarkers.  
The molecular heterogeneity within cancer types further complicates the prediction of 
tumor cell behavior determining a patient's drug response. Multiple somatic 
mutations, epigenetic events or otherwise deregulated gene/protein expression may 
contribute to driving the disease. This is true in acute myeloid leukemia (AML), 
where patients may harbor somatic mutations in a number of potential oncogenes 
including FLT3, MLL, TYK2, FGFR1, PDGFRA, IDH1, DNMT3A, impacting 
expression of downstream signaling for example through PIM kinases [5,6,7]. FLT3 
internal tandem duplications (FLT3-ITD) and PIM over-expression are associated 
with poor prognosis in AML patients, motivating the development of small molecule 
inhibitors targeting these proteins [8,9]. Incomplete signaling inhibition or the 
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presence of multiple molecular alterations that reduce a tumors dependency on any 
one target may result in drug resistance [10,11]. This may be overcome through 
rational drug combinations; however optimal approaches are rarely obvious and high 
throughput combination screening is complex and expensive with limited success 
shown.  
With an aging population, the incidence of AML is increasing, with the number of 
new cases per year approaching 20,000 in the USA alone. AML therefore presents a 
large unmet clinical need, with overall 5-year survival rates remaining at around 25%.  
Most patients will respond to initial cytoreductive therapy but a large proportion will 
relapse with emergence of drug-resistant clones. Given that bone marrow 
transplantation as the only curative therapy is not an option for many patients, a better 
understanding of the regulatory pathways causing leukaemic transformation and in 
particular the emergence of resistance will be essential to improve treatment outcomes 
in AML.  
Computational simulations of cancer cell signaling have the potential to overcome 
both the limitation of cell line diversity and in-vitro screening throughput. 
Computational modeling approaches can be used to capture and integrate knowledge 
with molecular and phenotypic data to better understand the genetic and signaling 
dependencies determining a drug’s mechanism of action. The models should be 
unique to the tumor cell context, include key proteins and their interactions whilst 
accounting for influential gene mutations, and would ideally extend to other 
molecules involved in cell signaling. Execution of such models should demonstrate 
the intracellular signaling activity as it is triggered by different mutations and 
different therapeutic modalities, resulting in different cell phenotypes.   
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Computational models based around Boolean networks, pioneered by Kauffman [12] 
as a model for genetic regulatory networks, have been demonstrated for interpretation 
of large data sets as well as for drug discovery [13,14,15]. In these models, 
relationships are represented in a dynamic network with discrete time steps. Signaling 
molecules represented by nodes in a network can have two states (hence a Boolean 
network) and edges are directed and may be activating or inhibitory, however this can 
over-simplify biological signaling where molecules often exist in multiple states with 
interactions that are rarely binary. Qualitative Networks (QN) make an extension to 
Boolean networks to allow variables to range over larger discrete domains by 
replacing Boolean functions with algebraic functions [16] (further details in 
supplementary methods). Specifically the graphical tool Bio Model Analyzer (BMA) 
[17] (available at http://biomodelanalyzer.research.microsoft.com/) has previously 
been used to encapsulate chronic myeloid leukemia (CML) cell signaling information 
from >150 publications in a QN model [18] able to then successfully recapitulate 
multiple independent experimental results. Another extention to Boolean networks is 
provided by Quantitative Modeling approaches, allowing variables to range over non-
discrete values and so capturing more complex relationships, but only feasible for 
much smaller, well-studied systems [19].  
In this study, we use QNs to model the protein signaling connecting genetic 
aberrations in FLT3, TYK2, PDGFRA or FGFR1 to cell proliferation/apoptosis via 
the PIM and PI3K kinases for four AML cell lines, accounting for their unique 
genetic and phenotypic diversity. Construction and analysis of the biological QN 
model was achieved in BMA [17]. By incorporating cell-specific context switches in 
the model for four cell lines, we were able to accurately model response and 
resistance to a pan-PIM kinase inhibitor AZD1208 and the FLT3 inhibitor AC220 and 
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validated experimentally our predictions. The model provides a useful tool for AML 
research, and the approach offers value to drug discovery and early development. 
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Materials and Methods 
Reagents 
AZD1208, AZD6244, and AZD5363 were synthesized by AstraZeneca R&D 
(Waltham, MA) and diluted in dimethyl sulfoxide (Sigma-Aldrich). AC220 and 
GDC0941 were purchased externally. 
Cell line treatment 
Cell lines (CMK, EOL1, HL60, KASUMI3, KG1A, MOLM13, MOLM16, 
MONOMAC6, MV411, NOMO1, OCIAML2, OCIM1, and OCIM2) were purchased 
from American Type Culture Collection (ATCC, http://www.atcc.org/) cell bank and 
passaged in our laboratory for fewer than 6 months after receipt or resuscitation.  
ATCC uses morphology, karyotyping, and PCR based approaches to confirm the 
identity of human cell lines and to rule out both intra- and interspecies contamination. 
All cells were cultured and assayed as previously described in [8] and in supplemental 
methods.  
Growth inhibition calculation 
For single agent, GI50 were calculated from the ratio of the 72 hour treatment to 72 
hour DMSO control, after subtraction of the Day 0 data from each measurement. The 
dose-response data were fitted using Xlfit (Microsoft Excel). For combination, 
percent growth inhibition was determined using the Chalice software with values of 0 
to 100% indicating anti-proliferation (fewer number of cells than the vehicle control 
but greater than or equal to the number of cells at the start of treatment) and values of 
101 to 200% indicating cell death (fewer cells than at the start of treatment).  Day 0 
values were subtracted from the Day 3 treatments. The combination Indexes (CI) and 
Synergy scores were determined using the software program Chalice (Zalicus) and CI 
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determination was made at the ED50 value. Synergy was determined by the Loewe 
additivity model. 
Full methods for gene expression microarray; whole exome DNA sequencing; and 
Theranositcs proteomics are in the Supplemental Methods, brief description follows.  
Gene expression microarray 
Cell line lysate was generated from logarithmic growing CMK, EOL1, HL60, 
KASUMI3, KG1A, MOLM13, MOLM16, MONOMAC6, MV411, NOMO1, 
OCIAML2, OCIM1, and OCIM2 cell lines. Lysate was sent to Expression Analysis 
(http://www.expressionanalysis.com/) for gene expression analysis on Affymetrix 
Human Genome U133 Plus 2.0 Array. Expression results were fRMA normalized, 
log2 transformed, and expression was averaged by gene symbol across probesets. 
Whole exome DNA sequencing 
Cell lines lysate was generated from logarithmic growing CMK, EOL1, HL60, 
KASUMI3, KG1A, MOLM13, MOLM16, MONOMAC6, MV411, NOMO1, 
OCIAML2, OCIM1, and OCIM2. Lysate was sent to Expression Analysis 
(http://www.expressionanalysis.com/) for whole exome DNA sequencing, and 
processed  with the BCBio pipeline (https://bcbio-nextgen.readthedocs.org). Paired 
analysis of the parental and resistant cell lines was performed to using FreeBayes 
[20], MuTect [21], and VarDict (GitHub) to call resistance specific mutations.  
Theranostics Health reverse phased protein array 
Cells were treated with AZD1208 or AC220 as single agent or in combination for 3 or 
24 hours. Lysate was prepared and shipped to Theranostics Health (Rockville, 
Maryland) for reverse phased protein array experiments.  
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Protein Array data transformation for executable network model construction 
The relative linear log2 RPPA values were categorized for use in executable network 
modelling (Fig S1) on a 5 point scale from 0-4 fitted to the distribution of the values 
(Table S1).  
Protein western blots 
 Cells were treated with AZD1208, AZ5363, or AC220 as single agent, combination, 
or resistance as experimentally described. Whole cell extracts were fractionated by 
SDS-PAGE and transferred to a nitrocellulose membrane in transfer buffer (500mM 
Glycine, 50mM TrisHCl, 0.01% SDS, 10% methanol) buffer at 20Volts for 90 
minutes using a semi-dry transfer apparatus according to the manufacturer’s protocols 
(Invitrogen). The membranes are blocked with 10% nonfat milk in TBS-T (10 mM 
Tris, pH 8.0, 150 mM NaCl, 0.5% Tween 20) for 1 hour and  washed three times  
with TBS-T and exposed to primary antibodies in 5% milk in TBS-T against 
pPRAS40 (CST 2997), p4EBP1 Ser 65 (CST 9451), pBAD (CST 9296), pp70S6 
(CST 9206), pS6 (CST 4858), pERK (CST 9106), pelF4B (CST 8151), pAKT(CST 
4058), α-tubulin (CST 2144) or β-actin (CST 4970) at 4 °C O/N.  Membranes are 
washed three times for 10 minutes and incubated with a 1:10000 dilution of 
horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies (CST 7074) 
for 1 hour at room temperature. After washing the membranes three times for ten 
minutes, signals were visualized using the ECL system (Thermo Scientific). 
PhosphoScan mass-spectrometry 
We confirmed the robusteness of our finding for MOLM16 cells treated with 2 uM 
AZD1208 for 3 hours (Table S2) by applying a LC-MS/MS phosphorylation 
proteomic approach. Additional details are provided in the Supplementary Note. 
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Targeted treatment of AML cell lines 
We investigated phenotypic and cell signaling responses by reverse-phased protein 
arrays (RPPA). Since the PIM gene family is often over-expressed [22,23,24] and 
FLT3-ITD’s are prevalent in AML [7], we treated the cells with the pan-PIM kinase 
inhibitor AZD1208 and the potent selective FLT3 inhibitor AC220 (Qizartinib) as 
monotherapy and in combination [25] and compared AML cell lines were treated with 
DMSO, 1uM AZD1208, 6nM  AC220, or the respective combination, for 3 or 24 
hours.  Lysates were generated, protein values were assessed by RPPA and quadrant 
median normalized (QMN) protein levels calculated (Table S3). Statistically 
significant total protein and phosphorylation changes were determined by log2 QMN 
differences greater than or equal to 0.5 and Wilcoxon Rank Sum Tests p-values less 
than or equal to 0.1 (Table S4).  
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Results  
AML cell lines show differential sensitivity to PIM inhibition 
To identify potential genetic alterations associated with sensitivity to the pan-PIM 
kinase inhibitor AZD1208, we surveyed gene variants by whole exome DNA 
sequencing (Table S5) and prioritized by AML disease relevance [7]. Although cells 
sensitive to AZD1208 do harbor AML relevant PDGFRA, FGFR1, FLT3, and MLL 
genetic variants, only a small number of cell lines harbor the same variant, thereby 
failing to reach statistical significance in association to drug response (Fig 1A). Basal 
cell line PIM1 mRNA expression tends to be higher in sensitive lines, as previously 
shown at the protein level [8], underlying the importance of compound target 
expression alongside the interplay with genetic alterations for sensitivity. However 
cells harboring pathway relevant genetic alterations or over-expressing PIM exhibit 
varied response to treatment, calling for a deeper examination of the cell signaling 
relating genotype to phenotype to provide a better understanding of the molecular 
dependencies underlying PIM inhibitor sensitivity in AML cell lines. 
Cell type-specific differences in PIM pathway signaling in response to treatment 
Given the wide variability of response to therapeutic agents across AML cell lines, we 
explored the differences in phospho-protein signaling downstream of PIM for AML 
cell lines MOLM16, MV411, EOL1 and KG1A. Reverse phase protein array (RPPA) 
measurements taken 24 hours post AZD1208 treatment reproduced published findings 
[8] of reduced BAD phosphorylation in the MOLM16 cell line, and reduced S6 
pS235/236 in EOL1 (Fig 1B). To estimate response of cell lines, growth inhibition 
was quantified according to the number of viable cells after culturing with different 
concentrations of AZD1208 and FLT3 inhibitor, AC220, in combination (Fig 1C, Fig 
S2). Directional de-phosphorylation signaling trends seen in RPPA for BRAF pS445, 
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EIF4B pS406, MTOR pS2481 and global BAD phosphorylation were confirmed by 
PhosphoScan mass-spectrometry in MOLM16 cells after 3 hour treatment with 
AZD1208 (Table S6). 
Building a generalized model of PIM signaling in AML 
In order to model the observed genotypic and phenotypic differences between the 
AML cell lines, we proposed a workflow for developing a cell-specific context 
network model using the BMA tool from cell line molecular information (Fig 2). We 
generated an initial generalized model from the manual curation of 68 publications 
(Table S7) for AML cell line. The initial model contains a canonical set of 64 
interactions among 32 interacting proteins connected to 2 cell phenotypes/behaviors 
of apoptosis and cell proliferation (http://www.bioc.cam.ac.uk/fisher/aml - 
GeneralModel.json, Table S8). All values at nodes range from 0 to 4 to represent the 
phosphorylation activity from the transformed RPPA data, with 0 representing low to 
no activity and 4 representing abnormal over activity. The cellular behavior outcome 
for each disease state is reflected by the two terminal downstream nodes, which model 
the outcome for cellular abnormal proliferation and apoptosis rates. The generalized 
model of AML signaling was able to capture only partial abnormal cell behavior for 
untreated cells, capturing the abnormal low apoptosis levels for both MOLM16 and 
MV411, and showing an increase in proliferation, yet not capturing the magnitude of 
the increase. In addition, known perturbations such as simulating inhibition of PIMs 
in the model, showed the expected trend line of decreased proliferation, yet did not 
exhibit the expected effect on apoptosis levels. 
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Introducing cell-specific context in QN models 
We incorporated multiple gene mutation switches 
(http://www.bioc.cam.ac.uk/fisher/aml -  CellSpecificAML.json, Table 1) to construct 
cell-specific context model. We iteratively refined the target function for each internal 
node to reflect the levels of phosphorylation activity as measured by the transformed 
RPPA data for each cell line as well as the qualitative activity reported in the 
literature in accordance to gene mutations. A cell-specific context in the model is 
simulated by setting the switches for the driver mutations found in that cell to 1, while 
all other switches to mutations that were assessed as non-driver are set to 0 (Table 
S9). As a result of different set of mutations “turned on” the protein activity exhibited 
by the model will differ between cell lines (Table S10). Additional details on data 
processing and model construction are in the Supplementary notes.  
Excutable QN model validated by cell type-specific signaling behaviour 
The executable QN model (Fig 3A) was built on the RPPA and growth inhibition of 
MOLM16 and MV411 cell lines, harboring TYK2 mutation and FLT3-ITD 
respectively (Fig 1B). For each cell line across each treatment (Fig 3B), the mean 
square error (MSE) observed between the transformed RPPA values and modeled 
signaling activity ranged from 0.15 to 0.21 and median of 0.17 (0.3 to 0.57 in the 
generalized model, median of 0.41), with the lowest seen for MV411 cell line treated 
with AZD1208 + AC220 combination and the highest for the MOLM16 cell line 
treated with AZD1208. Meanwhile across each protein, the MSE observed between 
the transformed RPPA values and each protein signaling activity ranged from 0 to 
0.36 and median of 0.29 (0.41 to 0.88 in the generalized model, median of 0.58), with 
the lowest seen for BAD and BCR and the highest seen for 4EBP1.  
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Equally as important, the cell-specific context model performed well in predicting 
cellular response as measured both by growth inhibition and markers of reduced 
proliferation and increased apoptosis (Fig 1B-C). The model accurately predicted (Fig 
3C) the reduction in proliferation as a result of treatment with AZD1208 single agent, 
AC220 single agent, and drug combinations in MV411 cells. Although under 
predicting the magnitude of increase in apoptosis for AC220 single agent, the model 
accurately predicted the directional responses with increases in apoptosis for 
AZD1208 single agent, AC220 single agent, and combination treatments in MV411 
cells. 
In addition to predicting differential phenoptypic responses in each cell line, the 
model highlights key signaling events that may underlie the mechanism for each. We 
validated the robustness of events suggested for MOLM16 using mass-spectrometry. 
Most importantly, the mass-spectrometry corroborated the decreased EIF4B pS406 
phosphorylation after AZD1208 treatment, contributing to decrease in proliferation, 
as well as the decrease in BAD pS112 and pS155 after AZD1208 treatment, which 
increases apoptosis. A key differentiating feature of MOLM16 cell lines is the lack of 
hyperactivity from the MAPK (Ras Raf MEK ERK) and AKT-mTORC1 pathways 
post AZD1208 treatment, supported by dephosphorylation at downstream BRAF 
pS445 and MTOR pS2481 in the mass-spectrometry data. 
Testing the adaptability of the model to new cell-specific contexts, we "turned on" the 
genetic alterations FIP1L1-PDGFRA fusion and FGFR1 fusion, matching EOL1 and 
KG1A cell lines respectively. The apoptosis range was expanded to span the full 
dynamic range seen in these cell lines, yet no further refinement of the model was 
performed. The model reflected the cellular signaling changes observed in RPPA data 
(Fig 3D) where the MSE ranged from 0.18 to 0.28 with the lowest seen for EOL1 cell 
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line treated with single agent AZD1208 and the highest for the KG1A cell line treated 
in combination with AC220. Across each protein, the MSE observed between each 
protein signaling activity and the transformed RPPA values ranged from 0 to 0.58, 
with the lowest seen for AKT and the highest seen for p27. The model also performed 
well in predicting cellular response (Fig 3E). For the proliferation and apoptosis cell 
behaviors, the model accurately predicted the cellular responses seen in KG1A for 
AZD1208, AC220, and combination treatments, as well as the cell behaviors for 
EOL1 with AZD1208 treatment (AC220 was not tested for EOL1). 
The model also replicated variations in sensitivity, such as EOL1 reacting with 
reduced apoptosis to PIM inhibition when compared to MOLM16. 
Novel signaling components proposed through model refinement 
A by-product of refining the QN model to capture cell type-specific signaling is a 
graphical and descriptive representation of cell specific signaling dynamics between 
proteins in the network (Fig 3A).  By simulating the QN model, we were able to test 
our assumptions regarding the signaling dependencies between proteins, as described 
by the target functions (Table 1). For instance, despite FLT3-ITD being upstream of 
PIM1, the effect revealed by the iterative optimization of the model was less than 
other interacting proteins, also suggested by the RPPA measurements (Fig 1A) 
leading to BAD over-activity in MOLM16 but not MV411. The target function of 
AKT shows that it is dependent on the activity of the FLT3-ITD and FGFR1 fusion, 
reflecting the accumulation of evidences for AKT/mTOR pathway role in AML 
(suggested previously by [8]). The target function of S6 reflects the dominant over 
activation of it via AKT-mTOR pathway, additive to the activity of MAPK pathway, 
and leading to anti-apoptotic cell behavior of MV411 and KG1A. At the same time 
the target function of BAD accumulates with activity of MAPK pathway and of PIM1 
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direct phosphorylation of all three sites of BAD [26] leading to the anti-apoptotic 
behavior observed in MOLM16. 
In silico virtual experimentation with AML cell models can replicate 
independently reported data 
As a first independent test of the AML cell-specific model, we assessed its ability to 
replicate in-silico a sample of protein and phenotypic cell line responses to drug 
treatment reported in the literature but not used as part of model construction or 
refinement. We replicated each in-vitro experiment by turning on a respected set of 
mutations and adding the new examined inhibitor to the model, then observing the 
predicted protein expression. All eight protein changes were successfully predicted 
(Table S11).  The model successfully predicted cell specific response to compounds 
including: failure of a MEK inhibitor to induce apoptosis in EOL1 [27]; insensitivity 
of KG1A to the combination of AKT, PDK1 and FLT3 inhibitors [28]; and the 
growth inhibition induced on EOL1 by combining PIM and AKT inhibition [11]. The 
decrease in cell proliferation of MV411 in response to mTORC [29] inhibitor was not 
recaptulated; however the authors of [29] attribute the decrease in proliferation to 
eIF4E decreased expression which was accurately replicated by the model.  
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AML cell-specific model predicts synergistic drug combinations with the PIM 
inhibitor 
To assess the potential to prioritize synergistic combinations through in silico 
hypothesis testing with these models we assessed the PIM inhibitor AZD1208, the 
AKT inhibitor AZD5363, MEK inhibitor selumetinib (AZD6244, ARRY-142886), 
FLT3 inhibitor AC220, and PI3K inhibitor AZ2426 across the 4 AML cell lines (Fig 
4A, Fig S3) also summarized in Table S12. For each cell line we simulated inhibiton 
of the drug targets first as single agents and then as combinations with PIM inhibition. 
We validated each combination in each cell line experimentaly across a dose range for 
each agent (Fig 4B). 
The MOLM16 cell line was correctly predicted to be hyper-sensitive to the PIM 
inhibitor resulting in almost complete cell kill, and no additional effect was predicted 
in combination with other inhibitors.   
In contrast, the MV411 context model, which habors a FLT3-ITD, correctly predicted 
a strong synergy between AZD1208 and AC220 combination attributed to apoptotic 
effect, evident even at lower dosage of combined treatments. Very weak synergy with 
mild apoptosis was correctly predicted in MV411 in combination with either MEK or 
PI3K inhibition.  
Meanwhile, EOL1 was correctly predicted to gain apoptotic synergic effect with the 
PIM and AKT inhibitor combination, as well as the PIM and PI3K inhibitor 
combination. Surprisingly, and the only synergy of the 16 combinations not predicted 
by the model, EOL1 also exibited a synergic effect with the AZD1208 and AC220 
combination. AC220 efficacy has previously only been reported in FLT3 driven 
tumors, however these data suggest efficacy from AC220 in PDGFRA mutated 
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tumors potetnially through inhibition of PDGFRA driven AKT/PI3K and MAPK 
signaling. 
Finally, in the KG1A model, which harbors an activating FGFR1 fusion, we did not 
see a co-occurrence of high apoptosis and high growth inhibition for any of the 
combination treatments, validated as well by the in-vitro assays. Our model suggests 
that the persistant insensitivity of KG1A may be derived by the high levels of cMyc, 
which is not directly targeted by any of the combinations.  
Executable QN model identify alternative susceptibilities in AZD1208 resistant 
cells 
Four separate populations of MOLM16 cells were made resistant to PIM inhibition by 
growth in the presence of increasing doses of the compound over a four month period 
until resulting cell populations were able to maintain growth at 1uM AZD1208. While 
the parental MOLM16 cell has a 50nM GI50 in a 3 day MTS proliferation assay, all 
four resistant populations had GI50s greater than 9uM to AZD1208 over the same 3 
day growth period (Fig S4A).  RPPA measurements were taken for the parental and 
resistant cell lines. 
We predicted candidate genetic causes of resistance by iteratively perturbing all 
individual and pairs of nodes in the parental MOLM16 model, and choosing those 
leading to similar signaling activity and phenotype as observed in the resistant 
populations, quantified by lower MSE (Fig S4B, S4C).  This resulted in four different 
resistant contexts, one for each resistant cell population (Fig 5A). All contexts show 
over-activation through RAS/PI3K as well as AKT/MTOR signaling, supported by 
RPPA (Fig S4B). Interestingly, the different resistance contexts differ in their strength 
of altered signaling where resistant cell population R1 has a higher activity for both 
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pathways and resistant cell population R3 has lower activity for the AKT pathway. 
The predicted and observed pathway signaling suggests increased signaling activity 
through 4EBP1, EIF4B, S6, and BAD contributing to resistance. In particular it 
highlights AKT-S6 pathway as a major cause for the decreased apoptosis compared to 
MOLM16 parental when treated with AZD1208. 
Whole exome DNA-seq was performed to identify potential protein altering genetic 
variants that could be driving the AZD1208 resistance. All variant calls with 
significant differences from the parental line (Table S13) were further parsed to 
highlight genes encoding proteins that have BIOGRID interactions (Table S14) to the 
RAS/PI3K and/or the AKT/MTOR signaling pathways (Fig 5B).  
Using the four resistant MOLM16 context models, we predicted possible treatments 
to overcome resistance by simulating inhibition at each point through systematic 
addition of an inhibitor node to the network. In line with signalling changes, 
introduction of an AKT inhibitor AZD5363 to the resistant populations was predicted 
to overcome the AZD1208 resistance by blocking the abnormal PRAS40, 4EBP1 and 
S6 activity (Fig 5D). To test this prediction, parental MOLM16 and AZD1208 
resistant populations were treated with and without 1uM AZD5363 for 1 hour. The 
resistant populations responded to AKT inhibition with AZD5363 by decreased 
pS235/235 S6 ribosomal protein and pT246 PRAS40 (Fig 5D), providing strong 
evidence for inhibition of AKT/MTOR signaling. The decrease in AKT/MTOR 
signaling was accompanied with an increase in cleaved PARP, indicating increased 
apoptosis and highlighting the dependency on this signaling pathway during 
AZD1208 resistance in MOLM16 cells. 
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Alternative qualitative modeling techniques 
Qualitative models provide coarse-grained descriptions useful for systems whose 
mechanistic underpinnings remain incomplete. The range of qualitative modeling 
approaches provide two major types of simplifications: Boolean models relax the 
activity of biological entities to binary (ON or OFF), alternatively the relation of 
entities may be relaxed to simple logic operators (AND, OR, NOT). We explored the 
use of alternative approaches and robustness of findings by building a Boolean model 
and an AND/OR model via the same pipeline. For single agent PIM-inhibitor 
treatment the Boolean model was able to reasonably predict the proliferation and 
apoptotic responses in MOLM16 and KG1a, partially predicted proliferation response 
in EOL1, but poorly predicted responses in MV411 (Fig S5).  The MV411 cell line 
was correctly predicted to response well to FLT3 inhibition.  The model was not, 
however, able to predict treatment combination synergies (Fig S5).  Since the Boolean 
model is simpler and easier to construct than a qualitative model it offers a useful tool 
for investigating single agent treatment in larger networks. 
The AND/OR gated model recaptured most of the responses to single treatments, as 
well as synergistic combinations, revalidating the predictions made by our model (Fig 
S6). The synergistic response of KG1a to the combination of AZD1208 and AC220 
was the only response not recaptured. This phenotype is likely derived by S6 additive 
activity from the MAPK pathway and AKT- mTORC1, which cannot be accurately 
described using AND/OR gates. AND/OR models may be generated by automated 
tools [30], and can serve well as an initial model scaffold. However more complex 
relationships such as those in our model between BAD, S6, 4EBP1, TSC2 and EIF4B 
in AML need to be further refined.  
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Discussion  
The success of personalizing treatments for AML patients by tailoring to respective 
genetic alterations that characterize cancer subtypes has so far been limited. 
Moreover, drug responses seen in genetically matched patients or representative cell 
lines show considerable diversity [10,7]. By integrating both genomic and baseline 
proteomic data from AML cell lines with known tumor-driving genetic events we 
generated an AML network model capturing cell-context-specific signaling in the 
PIM kinase pathway. We developed a workflow methodology for constructing a 
network model with cell-specific context switches, which focuses on iterative 
refinement of the target function to reflect literature and experimental evidences. 
Users may also consider applying automated tools to decipher the target functions, 
such as CellNOpt-cFL tool developed by Morris et al. [30], and follow by manual 
refinement of the target functions. 
The resulting cell-specific model captures cell specific signaling and response to 
cancer therapeutics, and provide virtual cell line models in which to test hypotheses 
for tailored therapy in silico. The cell-specific model significantly reduced the 
prediction error for both the baseline training data and on-treatment changes in protein 
expression compared to the generalized model. This is unsurprising since a 
generalized AML model insufficiently explains the heterogeneity in the mutational 
landscape and protein-signaling dynamics reported across different cell lines, for 
example a lack of signaling through AKT unique to cells with mutations in TYK2. 
 The cell-specific model accurately and directly recapitulated published experimental 
results for reported changes in expression in all 8 cases, and 9 out of 10 responses in 
cell behavior. These results are particularly remarkable when considering the potential 
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variability in signaling and phenotypic output over time, and the focus of these 
models on the cells steady state reflected by model stability. 
We progressed to experimentally validate predictions made with the cell-specific 
model. The MV411 context model captured the signaling impact of the FLT3-ITD to 
correctly predict induction of apoptosis after treatment with PIM and PI3K inhibitors, 
and no effect with PI3K inhibitor alone [11]. For the cell line KG1A we identified 
contribution of high cMyc activity to cell proliferation, and correctly predicted 
insensitivity to inhibition of targets thought to be elevated by the FGFR fusion [28] 
including AKT, PDK1 and FLT3. The EOL1 context model identified previously 
unreported combination synergy between PIM and PI3KCA inhibitors, validated 
through increased tumor growth inhibition. This could lead to patients treated with 
lower doses of the inhibitors if the same efficacy is achieved by combinations, and 
thereby, reducing the risk of toxicity. 
Model discrepancies highlight potential gaps in the captured network knowledge, and 
hypotheses that warrant further investigation. For example, our model fails to capture 
BCR and ERK overexpression following treatment in EOL1 and KG1a cell lines.  
This cannot be resolved through simple optimization of the current network, 
suggesting a potential gap in our knowledge of how the MAPK pathway influences 
these mechanisms (Fig 3D). We found that Siendones et al. [31] had also previously 
hypothesized the coexistence of transduction signal event, triggering the MAPK 
pathway independent of the FLT-ITD event, and coupled with poor response to FLT3 
inhibitor. Investigating this discrepancy may shed new light on the resistance 
mechanism of these patients to FLT inhibitors. 
Furthermore, using the MOLM16 context model we were able to systematically 
explore genetic changes that may render the cell resistant to PIM inhibition. Exome 
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sequencing and subsequent drug combination treatment of MOLM16 cell populations 
with acquired resistance to AZD1208 confirmed our predicted mechanistic 
dependency on AKT signaling and AKT inhibition as a second line therapy to 
overcome resistance. 
By accurately predicting drug responses and combination synergies, and providing the 
mechanistic insight on the proteins driving the response, we highlight the ability of 
simulated models and virtual experimentation to prioritize effective therapies 
accompanied with associated predictive and dynamic biomarkers. Successful drug 
combinations could significantly augment therapy options for AML patients by 
overcoming innate and acquired resistance to drugs. Simulated qualitative models 
potentially offer a virtual platform to screen, discover and prioritize drug 
combinations in silico, focusing experimental approaches to validation. 
Comprehensive genetic diagnosis using targeted exome sequencing is already 
entering the clinic in major teaching hospitals. When coupled with emerging mass 
cytometry analysis (PMID: 26095251), all the biological information to build patient 
specific qualitative networks models may soon be available from frontline diagnostics 
data.  
Taken together, the complexity of signaling pathways and the large number of 
resistance mechanisms mean that executable cellular models which are easily and 
quickly interpretable, like the ones we have presented here, are key for pinpointing 
potential combination therapies for different cancer types and subtypes. Furthermore, 
scaling these executable models to simulate patient-specific cancers paves the way for 
improved personalized treatments and enhanced precision medicine choices. 
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Table 1. Target functions for AML cell specific calibrated AML model. 
Target functions are associated to the nodes and aim to capture biological 
relationships. MAX function corresponds to independent activation by upstream 
proteins, while MIN corresponds to dependent activation, such that the effect is 
governed by the lower expression of the two upstream proteins. + corresponds to 
an additive effect, and * is used to assign magnitude of effect. Table S1 extends 
this table and includes the Generalized Model and experimental and literature 
supporting evidences for each target function. 
Protein/Node Cell-Specific Model Target Function 
PIM1 max(3/4*FltITD,TYK2,3/4*PDGFRA,FGFR1) 
 PIM2 max(FltITD,1/2*TYK2,1/2*PDGFRA) 
BAD 1/2*RSK+1/2*PIM1 
EIF4B min(3,RSK+1/2*PIM1) 
EIF3 min(EIF4E,EIF4B) 
4EBP1 2/3*mTORC1+1/6*EIF3+1/6*PIM2 
EIF4E max(1/2*4EBP1,S6) 
S6 1/8*RSK+3/4*mTORC1+1/8*EIF3 
 BCR max(1, 1/2*FltITD) 
Grb2/SOS max(BCR,1/2*FGFR1) 
RAS min(Grb2/SOS,BCR) 
PI3K max(BCR,Grb2/SOS,1/2*PDGFRA) 
RAF AVG(RAS) 
MEK AVG(RAF) 
ERK max(MEK,1/2*PDGFRA) 
RSK AVG(ERK) 
AKT max(PI3K,mTORC2) 
mTORC2 AVG(PI3K) 
mTORC1 1/2*PRAS40+TSC2 
 TSC2 1/2*((PIM2-1)+1/2*Akt) 
PRAS40 1/4*PIM1+5/4*Akt 
 CHK max(PIM1,PIM2) 
H3 AVG(CHK) 
cMyc max(3/4*FGFR1,max(1,1/4*(max(PIM1,PIM2) + H3)) 
P27 max(1,var(cMyc)*(var(cMyc)-
 Proliferation (EIF4B-2)+1/2*ERK+2/3*p27+2/3*cMyc 
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Apoptosis !MAX(BAD, S6, 1/2*BAD + cMyc + S6 + 2*EIF4E))  
*  d d b   f    
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Figure 1. AML cell lines sensitive to the PIM inhibitor AZD1208 have diverse 
genotypes. (A) GI50 (uM) waterfall plot and molecular oncoprint illustrating the 
diverse pharmacological response of AML cells after 72 hours AZD1208 treatment as 
well as PIM expression and AML disease relevant mutations. Boxed cell lines names 
indicate responding cell lines further investigated. (B) Protein expression measured by 
reverse-phase protein array (RPPA) in treated and untreated cell lines show 
heterogeneity in signaling responses through various pathways. (C) MV411, with an 
active FLT3-ITD, shows varied responses to concentrations of AZD1208 and/or 
AC220 for 72 hours. The number of viable cells was determined by Alamar Blue 
measurements where the values represent percent growth inhibition. 
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Figure 2. Schematic workflow of cell-specific model construction in BMA. Motifs 
and interactions curated from the literature are used to build a Qualitative Network in 
the BMA tool. The model was calibrated with the results of RPPA experiments for 
two cell lines with different AML-driving mutations. The model is designed to 
represent the general AML pathways, and provide a cell-specific context by “turning-
on“ a specific set of mutations. The mutations impact outgoing interactions, thus 
activating the pathways in a mutation-specific manner, resulting in mutation-specific 
phosphorylation activity throughout the pathways leading to specific cellular 
behavior. The model is iteratively refined by testing and comparing to the cell 
behavior measured as a response to different perturbations for the two cell lines. The 
model robustness was tested against perturbations from the literature performed on 
the explored mutations, and unseen cell lines incorporated automatically into the 
model. The model is then used for in-silico experimentation in order to test novel drug 
combinations, infer the source and mechanism for drug resistance, and predict drug 
response in resistant cell lines and suggest treatment for resistance. 
Cancer Research 
 
35 
 
Figure 3. Generation of a predictive cell behavior model for AML training cell 
lines (MOLM16 and MV411) and unseen cell lines (EOL1 and KG1A) (A) Cell-
Specific AML regulatory network model incorporating knowledge from the literature 
and calibrated to phosphorylation activity measured by RPPA. Perturbations, driving 
mutations, and internal genes are depicted in grey, green, and red, respectively. To 
simulate specific cell (MOLM16, MV411, EOL1 or KG1A) the node for the protein 
with driver mutations (TYK2, FLT-ITD, PDGFRA, or FGFR1 respectively) is set to 
1, while all other proteins with mutations are set to 0.  (B) Protein signaling activity 
(phosphorylation) levels inferred in-silico using the cell-specific contexts (laptop 
icon), and the generalized model (papers icon) capturing levels of phosphorylation 
activity as measured in-vitro (petri-dish). (C) Cell apoptosis and proliferation as 
inferred in-silico by the executable model compared to levels as observed in-vitro, 
with the generalized model capturing partial abnormal cell behavior, and the cell-
specific context model recapitulating measured levels. (D) Unseen cell lines EOL1 
and KG1A are incorporated to the executable network model. The robustness of the 
model is tested via the ability of the model to capture the phosphorylation activity 
unseen at the time of model construction, and (E) Cell behavior as a result of different 
perturbations. 
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Figure 4. Validation of predicted synergistic combinations of drugs reveals new 
effective treatment strategies. (A) Cell-Specific AML model is used to test 
combinations of drugs and predict cell behavior in a cell specific manner. A drug or a 
combination of drugs is simulated by partially or fully nullifying the target functions 
of their targets, and can be done automatically and efficiently with a large number of 
candidates. (B) Predicted cell behavior of apoptosis and proliferations is validated via 
growth inhibition of AML cell lines cultured with the indicated concentration ranges 
of AZD1208 and/or tested combined inhibitor after 72 hours. Predicted synergic 
effect, as seen for EOL1 cell line with PIM and AKT and PIM and PI3K inhibitors, is 
used to prioritize combinations. 
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Figure 5. Origin of resistance to AZD1208 in MOLM16 is computationally 
inferred and validated via whole exome DNA-seq, revealing signaling mechanism 
validated via western blots and offers combination to combat resistance which 
successfully induces apoptosis. (A) Network model of MOLM16 resistant cell 
populations (R1-4). Perturbations (lightning bolts) were automatically predicted at 
specific nodes to simulate possible resistance mechanisms that would attenuate 
signaling down a specific pathway (shaded red and blue). (B) Whole exome DNA-seq 
was performed on the 1uM AZD1208 resistant pool population to identify protein 
altering variants from variant calling as significantly different from the parental 
MOLM16 cell line. Genes whose proteins are involved with epigenetic machinery are 
underlined with dashes. (C) Inferred signaling activity from the parental MOLM16 
executable model is compared to activity from western blots for parental and resistant 
cell populations. (D) Predictions of signaling activity and cell apoptosis for AZD1208 
treated alone and in combination with AKT inhibitor AZD5363 is compared to 
activity from western blots. Prediction of induced apoptosis is supported by the 
increase in PARP Cleaved with AZD5363. 
 
 
 
 
 
